RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
ABIOMED Stock

ABIOMED Revenue 2025

ABIOMED Revenue

1.54 B USD

Ticker

ABMD

ISIN

US0036541003

WKN

873886

In 2025, ABIOMED's sales reached 1.54 B USD, a 14.93% difference from the 1.34 B USD sales recorded in the previous year.

The ABIOMED Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2027e1.8146,61
2026e1.7149,30
2025e1.5454,78
2024e1.3462,95
2023e1.1672,85
20221.0381,76
20210.8580,90
20200.8482,01
20190.7783,17
20180.5983,41
20170.4584,15
20160.3384,70
20150.2382,67
20140.1879,68
20130.1680,01
20120.1380,62
20110.178,26
20100.0973,75
20090.0772,13
20080.0674,53
20070.0576,28
20060.0473,23
20050.0475,65
20040.0370,43
20030.0267,81

ABIOMED Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into ABIOMED, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by ABIOMED from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects ABIOMED’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of ABIOMED. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into ABIOMED’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing ABIOMED’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on ABIOMED’s growth potential.

ABIOMED Revenue, EBIT and net profit per share

DateABIOMED RevenueABIOMED EBITABIOMED Net Income
2027e1.81 B USD510.11 M USD440.82 M USD
2026e1.71 B USD470.09 M USD367.88 M USD
2025e1.54 B USD408.5 M USD315.97 M USD
2024e1.34 B USD333.59 M USD256.58 M USD
2023e1.16 B USD271.28 M USD221.46 M USD
20221.03 B USD256.71 M USD136.51 M USD
2021847.5 M USD229.6 M USD225.5 M USD
2020840.9 M USD249.2 M USD203 M USD
2019769.4 M USD224.8 M USD259 M USD
2018593.7 M USD157.1 M USD112.2 M USD
2017445.3 M USD90.1 M USD52.1 M USD
2016329.5 M USD65.1 M USD38.1 M USD
2015230.3 M USD28.7 M USD113.7 M USD
2014183.6 M USD8.4 M USD7.4 M USD
2013158.1 M USD16.5 M USD15 M USD
2012126.4 M USD1.5 M USD1.5 M USD
2011101.2 M USD-11.2 M USD-11.8 M USD
201085.7 M USD-25.1 M USD-19 M USD
200973.2 M USD-29.5 M USD-31.6 M USD
200858.9 M USD-35.3 M USD-40.9 M USD
200750.6 M USD-27.7 M USD-27.9 M USD
200643.7 M USD-17 M USD-29.4 M USD
200538.2 M USD-3.3 M USD-2.3 M USD
200425.7 M USD-10.3 M USD-9.4 M USD
200323.3 M USD-19.5 M USD-18.2 M USD

ABIOMED stock margins

The ABIOMED margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ABIOMED. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ABIOMED.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the ABIOMED's sales revenue. A higher gross margin percentage indicates that the ABIOMED retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the ABIOMED's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the ABIOMED's total revenue generated. When comparing the revenue margin year over year, investors can gauge the ABIOMED's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the ABIOMED. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the ABIOMED's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

ABIOMED Margin History

ABIOMED Gross marginABIOMED Profit marginABIOMED EBIT marginABIOMED Profit margin
2027e81.76 %28.18 %24.35 %
2026e81.76 %27.47 %21.5 %
2025e81.76 %26.53 %20.52 %
2024e81.76 %24.89 %19.15 %
2023e81.76 %23.43 %19.12 %
202281.76 %24.88 %13.23 %
202180.9 %27.09 %26.61 %
202082.01 %29.63 %24.14 %
201983.17 %29.22 %33.66 %
201883.41 %26.46 %18.9 %
201784.15 %20.23 %11.7 %
201684.7 %19.76 %11.56 %
201582.67 %12.46 %49.37 %
201479.68 %4.58 %4.03 %
201380.01 %10.44 %9.49 %
201280.62 %1.19 %1.19 %
201178.26 %-11.07 %-11.66 %
201073.75 %-29.29 %-22.17 %
200972.13 %-40.3 %-43.17 %
200874.53 %-59.93 %-69.44 %
200776.28 %-54.74 %-55.14 %
200673.23 %-38.9 %-67.28 %
200575.65 %-8.64 %-6.02 %
200470.43 %-40.08 %-36.58 %
200367.81 %-83.69 %-78.11 %

ABIOMED Aktienanalyse

What does ABIOMED do?

Abiomed Inc. is one of the most innovative companies in the medical technology industry. It was founded in 1981 and is headquartered in Danvers, Massachusetts. The company specializes in the development, manufacturing, and marketing of medical devices aimed at saving or improving patients' lives. Abiomed started as a small company focused on implantation technology for cardiac arrhythmias. However, the company soon recognized the need to concentrate on providing solutions for cardiac intensive care. Today, Abiomed is a leader in the field of cardiopulmonary support systems and offers innovative devices to support the heart. Abiomed's business model revolves around leveraging its expertise in medical technology for cardiology interventions and intensive care and bringing innovative products to market. The company has industry experts and doctors on its team who contribute to the development and manufacturing of products. This highest level of professionalism is also reflected in the distribution channels Abiomed utilizes, with a focus on delivering its products to clinics specialized in critical medical interventions. Abiomed is divided into various business segments that concentrate on the medical devices the company offers. One of these segments is the Impella portfolio, which focuses on heart pumps for acute heart failure. These pumps are capable of supporting the heart during cardiological intervention by pumping blood into the heart while artificially ventilating it. The Impella portfolio is recognized as a standard in cardiac intensive care. Another important area for Abiomed is product development. The company heavily invests in researching and developing new products to meet the current demand in cardiology on the market. Abiomed is aware that rapid development of new products can provide a competitive advantage and, therefore, is an essential part of its business model. The technology offered by Abiomed is revolutionary and allows for the treatment of patients with acute heart failure, which was previously difficult or impossible. This is a significant milestone for the company and the healthcare industry in general. Abiomed is aware of its responsibility towards patients, doctors, and hospitals and is continuously working to develop innovative solutions for the healthcare industry. In summary, Abiomed Inc. is a leading company in the medical technology industry that focuses on cardiology intervention and intensive care. The company is innovative and offers products that can save and improve patients' lives. The Impella portfolio, specializing in acute heart failure, is an important part of its business model. Abiomed heavily invests in research and development to consistently provide innovative solutions to its customers. ABIOMED ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding ABIOMED's Sales Figures

The sales figures of ABIOMED originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing ABIOMED’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize ABIOMED's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in ABIOMED’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about ABIOMED stock

How much revenue did ABIOMED generate this year?

ABIOMED has achieved a revenue of 1.54 B USD this year.

How much was the turnover of the company ABIOMED compared to the previous year?

The revenue of ABIOMED has increased by 14.93% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of ABIOMED?

The revenue of ABIOMED is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of ABIOMED measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of ABIOMED so important for investors?

The revenue of ABIOMED is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does ABIOMED pay?

Over the past 12 months, ABIOMED paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ABIOMED is expected to pay a dividend of 0 USD.

What is the dividend yield of ABIOMED?

The current dividend yield of ABIOMED is .

When does ABIOMED pay dividends?

ABIOMED pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ABIOMED?

ABIOMED paid dividends every year for the past 0 years.

What is the dividend of ABIOMED?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ABIOMED located?

ABIOMED is assigned to the 'Health' sector.

Wann musste ich die Aktien von ABIOMED kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ABIOMED from 2/2/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 2/2/2025.

When did ABIOMED pay the last dividend?

The last dividend was paid out on 2/2/2025.

What was the dividend of ABIOMED in the year 2024?

In the year 2024, ABIOMED distributed 0 USD as dividends.

In which currency does ABIOMED pay out the dividend?

The dividends of ABIOMED are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The ABIOMED stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von ABIOMED

Our stock analysis for ABIOMED Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ABIOMED Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.